Sanofi (NASDAQ:SNY) Lifted to “Strong-Buy” at StockNews.com

Sanofi (NASDAQ:SNY) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Wednesday.

Several other analysts have also commented on SNY. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Argus raised their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Three analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Down 0.6 %

SNY stock opened at $57.31 on Wednesday. The firm has a market cap of $145.43 billion, a PE ratio of 28.80, a P/E/G ratio of 1.62 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm’s fifty day moving average is $55.31 and its 200 day moving average is $50.97. Sanofi has a one year low of $42.63 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business earned $0.95 earnings per share. On average, research analysts forecast that Sanofi will post 4.26 EPS for the current year.

Hedge Funds Weigh In On Sanofi

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. POM Investment Strategies LLC purchased a new position in Sanofi during the second quarter valued at $25,000. Register Financial Advisors LLC purchased a new position in shares of Sanofi in the first quarter worth about $29,000. Larson Financial Group LLC lifted its stake in shares of Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after buying an additional 500 shares in the last quarter. Palisade Asset Management LLC purchased a new position in shares of Sanofi in the first quarter worth about $31,000. Finally, Arrow Financial Corp purchased a new position in shares of Sanofi in the second quarter worth about $35,000. 10.04% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.